Dua Asim: Efficacy and Safety of Rivaroxaban Plus Aspirin in PAD Patients
Dua Asim, Third-Year Medical Student at Jinnah Sindh Medical University, shared a post on LinkedIn about a recent article she and her colleagues co-authores, published in Annals of Medicine and Surgery, adding:
“I am pleased to share our recently published systematic review and meta-analysis, ‘Efficacy and Safety of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Peripheral Arterial Disease,’ published in Annals of Medicine and Surgery.
This study evaluates dual pathway inhibition using rivaroxaban plus aspirin in patients with peripheral arterial disease.
Our findings suggest that combination therapy may improve cardiovascular and limb-related outcomes; however, it also underscores the importance of careful, individualized risk assessment due to an increased risk of major bleeding.
I am sincerely grateful to my co-authors for their dedication, collaboration, and valuable contributions to this work.”
Title: Efficacy and safety of rivaroxaban plus aspirin compared with aspirin alone in patients with peripheral arterial disease: a systematic review and meta-analysis
Authors: Muhammad Farhan, Syed Hassan Ali, Daniyal Khalid, Adina Kazmi, Dua Asim, Zoha Idrees, Muhammad Saim Siddiqui, Sudais Bin Sohaib, Muhammad Saad Khan, Muhammad Mohsin Khan, Abubakr Mahmoud
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas Lang։ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge